<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181232</url>
  </required_header>
  <id_info>
    <org_study_id>STCR-0901-TW</org_study_id>
    <nct_id>NCT01181232</nct_id>
  </id_info>
  <brief_title>A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients</brief_title>
  <official_title>A Randomized, Active Control, Parallel Study to Evaluate the Efficacy and Safety of Zolpidem MR (Stilnox CR) Versus Zolpidem (Stilnox) in Patients With Primary Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Taiwan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of zolpidem MR (modified
      release) compared to zolpidem IR (immediate release) in patients with primary insomnia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rest/activity cycles measured by Actigraphy</measure>
    <time_frame>For 2 weeks (Day 0, Day 7, Day 14)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total score of Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>For 2 weeks (Day 0, Day 7, Day 14)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician's clinical global impression (CGI)</measure>
    <time_frame>For 2 weeks (Day 0, Day 7, Day 14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global impression (PGI)</measure>
    <time_frame>For 2 weeks (Day 0, Day 7, Day 14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep latency as derived from sleep diary</measure>
    <time_frame>For 2 weeks (Day 0, Day 7, Day 14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of awakenings as derived from sleep diary</measure>
    <time_frame>For 2 weeks (Day 0, Day 7, Day 14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total sleep time as derived from sleep diary</measure>
    <time_frame>For 2 weeks (Day 0, Day 7, Day 14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wake time after sleep onset as derived from sleep diary</measure>
    <time_frame>For 2 weeks (Day 0, Day 7, Day 14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day time function as assessed by Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>For 2 weeks (Day 0, Day 7, Day 14)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <condition>Primary Insomnia</condition>
  <arm_group>
    <arm_group_label>MR low-dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MR high-dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IR group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem MR</intervention_name>
    <description>oral</description>
    <arm_group_label>MR low-dose group</arm_group_label>
    <arm_group_label>MR high-dose group</arm_group_label>
    <other_name>Stilnox CR</other_name>
    <other_name>Ambient CR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem IR</intervention_name>
    <description>oral</description>
    <arm_group_label>IR group</arm_group_label>
    <other_name>Stilnox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary insomnia based on DSM-IV criteria (307.42)

          -  Written informed consent has been obtained

        Exclusion Criteria:

          -  Patients with sleep apnea syndrome, narcolepsy, presence or suspicion of periodic leg
             movement or restless leg syndrome

          -  Patients with hepatic failure, myasthenia gravis, or hypersensitivity to zolpidem

          -  Patients who are known to be current drug or alcohol abuser or likely to concomitantly
             consume alcoholic beverages (more than 3 times/week)

          -  Patients who have received antihistamines or antipsychotics will not allow to
             discontinue the previous medication throughout the study

          -  Patients who are pregnant, lactating or intend to become pregnant during the study
             period

          -  Patients who have received antidepressants or anxiolytics will not allow to change the
             dose or discontinue the previous medication throughout the study

          -  Any clinically significant condition, which in the opinion of the investigator makes
             the patients unsuitable for the trial

          -  Participation in any clinical trial within 1 month prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch_e.jsp</url>
    <description>Link to Results on JAPIC - enter 140534 in the JapicCTI-RNo. field</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>September 9, 2014</last_update_submitted>
  <last_update_submitted_qc>September 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insomnia</keyword>
  <keyword>zolpidem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

